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This study aims to report the outcomes of nitinol and polytetrafluoroethylene covered stent placement to treat hemodialysis
arteriovenous access stenosis at a single center over a five-year period. Clinical and radiological information was reviewed
retrospectively. Poststent primary and secondary patency rates were determined using Kaplan-Meier analysis. Ten clinical variables
were subjected to multivariate Cox regression analysis to determine predictors of patency after stent placement. During the study
period 60 stents were deployed in 45 patients, with a mean follow-up of 24.5 months. The clinical and anatomical success rate was
98.3% (59/60). Poststent primary patency rates at 6, 12, and 24 months were 64%, 46%, and 35%, respectively. Poststent secondary
patency rates at 6, 12, and 24 months were 95%, 89%, and 85%, respectively. Stent placement for upper arm lesions and in access
less than 12 months of age was associated with reduced primary patency (adjusted hazards ratio [HR] 5.1, 𝑝 = 0.0084, and HR
3.5, 𝑝 = 0.0029, resp.). Resistant or recurrent stenosis can be successfully treated by endovascular stent placement with durable
long-term patency, although multiple procedures are often required. Stent placement for upper arm lesions and in arteriovenous
access less than 12 months of age was associated with increased risk of patency loss.
1. Introduction
The provision of hemodialysis for patients with end-stage
kidney disease requires a functioning arteriovenous vascular
access. This is achieved through surgical creation of an
arteriovenous anastomosis using either native vessels (arteri-
ovenous fistulae, AVFs) or prosthetic material (arteriovenous
grafts, AVGs). With repeated use, these can become dys-
functional, most commonly due to neointimal hyperplasia
resulting in stenosis [1]. Vascular access dysfunction con-
tinues to be a major cause of morbidity and mortality and
represents a significant proportion of the costs associated
with hemodialysis care [2].
Percutaneous transluminal angioplasty is commonly used
to treat arteriovenous access stenosis and is established prac-
tice inmany centers around theworld [1]. Despite this, lesions
treated with balloon angioplasty are prone to restenosis; at
12 months, approximately half of all AVFs require repeated
intervention to maintain patency [3, 4]. Factors such as
increased lesion length, upper arm AVFs, and younger AVF
age have been shown to be associated with patency loss after
balloon angioplasty [5]. Specific locations are alsomore prone
to recurrent stenosis, particularly the juxta-anastomosis in
radiocephalic AVFs and cephalic arch in brachiocephalic
AVFs [6]. In situations of resistant or recurrent stenosis early
after angioplasty, endovascular stent placement should be
considered and may prolong access patency [7].
The aim of this study was to report our experience
using vascular stents (self-expanding nitinol and polytetraflu-
oroethylene (PTFE) covered stents) for the treatment of
resistant and recurrent stenosis and to determine if therewere
any predictors of patency after endovascular stent placement.
2. Methods
The human research ethics committee for the Cairns Hos-
pital and Hinterland Health Service approved the study
(HREC/13/QCH/120-872). Informed patient consent was
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waived due to the retrospective nature of the study.
Hemodialysis vascular access and radiology databases were
searched to identify all stent placements for vascular access
stenosis and to determine long-term patency outcomes.
2.1. Setting and Patients. All patients who underwent stent
placement for resistant or recurrent hemodialysis access
stenosis (both AVFs and AVGs) between January 2008 and
December 2012 at Cairns Hospital were included.
2.2. Indications for Stent Placement. Indications for the
placement of self-expandable nitinol stents (LifeStent and
E-Luminexx; Bard Peripheral Vascular) were (1) recurrent
stenosis, defined as restenosis of a previously treated lesion
within three months of balloon angioplasty, and (2) resistant
stenosis, defined as greater than 30% stenosis of the treated
lesion after ultra-high pressure balloon inflation at recom-
mended burst pressure.
Indication for the placement of PTFE covered stents
(FLUENCY Plus; Bard Peripheral Vascular, Viabahn; GORE,
and Advanta; Atrium) was recurrent stenosis within three
months of angioplasty in the cephalic arch or central veins, at
the discretion of the operator. The cephalic arch was defined
as the proximal five centimeters of the cephalic vein. The
central veins were defined as the subclavian and innominate
veins and superior vena cava.
Arteriovenous access was investigated for recurrent
stenosis on the basis of the following standardized monitor-
ing and surveillance techniques: decreased or absent thrill,
difficult cannulation, prolonged bleeding time after dialysis,
development of collateral veins, excessive dynamic venous
pressures on three consecutive occasions, decreased arterial
blood flow (fistula blood flow rate < 500mL/min; Flow-QC;
Transonic Systems, Ithaca, New York) or decreased blood
flow bymore than 25% of baseline, or abnormal recirculation
measurements (>10%) [6, 8]. Radiological confirmation was
established following diagnostic contrast fistulography.
2.3. Definition of Treatment Areas. Location of stent place-
ment was classified according to a seven-zone system mod-
ified from previous studies (Figure 1) [4, 8]: arterial inflow,
anastomosis, juxta-anastomosis (distal 5 cm of cephalic vein
adjacent to the arteriovenous anastomosis), forearm venous
outflow, upper arm venous outflow, cephalic arch (proximal
5 cm of the cephalic vein), and central veins. In the case of
brachiobasilic saphenous vein grafts and PTFE grafts, vein-
vein anastomotic stenosis and vein-graft anastomotic stenosis
were grouped with juxta-anastomotic stenosis.
2.4. Procedural Details. Stent placement was performed
using standard techniques previously published by our center
[6, 8]. Imaging from the cannulation site to the right atrium
was obtained using intravenous contrast. A vascular sheath
and guide wire were used to obtain access to the lesion.
Intermediate, high pressure and ultra-high pressure balloons
were used at recommended burst pressure to treat stenotic
lesions. Bare metal self-expandable nitinol stents (LifeStent
and E-Luminexx; Bard Peripheral Vascular) and covered
stents (FLUENCY Plus; Bard Peripheral Vascular, Viabahn;
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Figure 1: Locations of stent deployment.
GORE, and Advanta; Atrium) were placed according to the
manufacturer’s recommended deployment technique. In all
instances attempt was made to achieve equal length of the
stent on either side of the lesion and postplacement balloon
dilatation was performed.
2.5. Study Endpoints and Statistical Analysis. Anatomical
success was defined as less than 30% residual stenosis after
stent placement and demonstrated continuity of the access
circuit on contrast study. Clinical success was defined as the
ability to provide uninterrupted hemodialysis at prescribed
access flow rates for three consecutive sessions using the same
access. Procedural complicationswere recorded and classified
according to the Society of Interventional Radiology guide-
lines [9].
Long-term patency was defined in accordance with the
Society of Interventional Radiology reporting standards fol-
lowing treatment with stent placement [10]. Postintervention
primary patency was defined as the interval after stent place-
ment until repeated percutaneous intervention is required
or the development of access thrombosis. Postintervention
secondary patency was defined as the interval after stent
placement until the access is surgically declotted, revised, or
abandoned. Open surgical repair was employed after failed
percutaneous salvage of stenosis, thrombosis, or pseudoa-
neurysm repair.
Data were recorded and analyzed using SPSS (version 21;
IBM, Armonk, New York). Continuous data were reported
as mean ± standard deviation. Kaplan-Meier curves were
used to determine poststent primary and secondary patency
rates. During follow-up, participants were censored because
of death with a functioning access, renal transplantation,
switch to peritoneal dialysis, or loss to follow-up. Univariate
and multivariate Cox regression analysis was performed to
determine if there were any predictors of patency after stent
placement. Ten variables were analyzed: patient age, gender,
indigenous ethnicity, diabetes, history of vascular disease
International Journal of Vascular Medicine 3
(stroke, coronary or peripheral artery disease), type of stent
(self-expandable nitinol or PTFE covered stents), access age
(time from creation to stent placement), type (native fistula
or native vein/prosthetic graft), lesion location (upper arm or
forearm), and antiplatelet therapy.
3. Results
During the five-year study period, 60 stent procedures were
performed in 45 cases of dysfunctional arteriovenous access
in 45 patients. The mean patient age was 57 years and
brachiocephalic AVFs were the most common type of access
(64%) (Table 1). The majority of patients (60%) were of
Aboriginal and/or Torres Strait Islander ethnicity. In 51 cases,
the treated lesion had undergone angioplasty on one previous
occasion with recurrence of stenosis within three months. In
six cases, the treated lesion had been treated with angioplasty
on two occasions, although stenosis had recurred beyond
three months after the first angioplasty. In three instances a
stent was placed during the index procedure due to resistant
stenosis despite ultra-high pressure balloon inflation at the
recommended burst pressure.
The location of stent placement according to type of arte-
riovenous access is presented in Table 2. Juxta-anastomotic
stenosiswas themost commonly treated area in radiocephalic
AVFs. In brachiocephalic AVFs, the cephalic arch was the
most frequent site of stent deployment.
The anatomical and clinical success rate was 98.3%
(59/60 procedures). Complications occurred in four cases.
Minor complications included one venous spasm and one
access hematoma that did not require specific treatment and
extravasation of contrast in another case that settled with bal-
loon tamponade. One procedure was unsuccessful because of
failed percutaneous thrombolysis, and stent placement was
abandoned. No major complications occurred.
Mean follow-up was 24.5 months (range: five days to 4.8
years). One patient was lost to follow-up 30 months after
stent placement due to relocation to another hospital. The
mean poststent primary patency was 14 months (standard
deviation ± 13 months) and the mean poststent secondary
patency was 25 months (standard deviation ± 18 months).
Poststent primary patency at 6, 12, and 24 months was 64%,
46%, and 35%, respectively (Figure 2). Poststent secondary
patency at 6, 12, and 24 months was 95%, 89%, and 85%,
respectively (Figure 3).
The mean poststent primary patency for both bare metal
and covered stents was 14 months (standard deviation ± 14
and 12 months, resp.).Themean poststent secondary patency
for bare metal stents was 29 months (standard deviation ± 20
months). The mean poststent secondary patency for covered
stents was 18 months (standard deviation ± 11 months).
Poststent primary patency rates for each of the seven
treated areas are presented in Figure 4.Therewas a significant
difference in poststent primary patency between the seven
treatment areas (log-rank 𝑝 = 0.00012). Stent placement
used to treat more central lesions above the elbow, especially
the upper arm venous outflow, cephalic arch, and central
veins, tended to result in poorer outcomes compared to juxta-
anastomotic stenosis and forearm venous outflow lesions.
Table 1: Baseline patient characteristics and intervention details.
Patients 45
Male (%) 53
Mean patient age (years) 57 ± 11
Mean follow-up (months) 25 ± 18
Indigenous ethnicity1 (%) 60
Access type
Brachiocephalic AVF 29
Radiocephalic AVF 11
Brachiobasilic saphenous vein graft 4
Brachiobasilic PTFE graft 1
Stent type
Nitinol stent 44
PTFE covered stent 16
Stent location (%)
Arterial inflow 0
Anastomosis 5
Juxta-anastomosis 28
Forearm venous outflow 7
Upper arm venous outflow 25
Cephalic arch 28
Central veins 7
1Aboriginal and/or Torres Strait Islander ethnicity.
Table 2: Stent location according to access type.
Radiocephalic AVFs (𝑛 = 15)
Arterial inflow 0
Anastomosis 3
Juxta-anastomosis 7
Forearm venous outflow 4
Upper arm venous outflow 0
Cephalic arch 0
Central veins 1
Brachiocephalic AVFs (𝑛 = 35)
Arterial inflow 0
Anastomosis 0
Juxta-anastomosis 7
Upper arm venous outflow 9
Cephalic arch 17
Central veins 2
Brachiobasilic saphenous vein/PTFE grafts (𝑛 = 10)
Arterial inflow 0
Anastomosis 0
Vein-vein or vein-graft anastomosis 3
Upper arm venous outflow 6
Central veins 1
During the follow-up period, 25 cases (42%) did not
require any further interventions tomaintain patency.Thirty-
five cases (58%) required multiple further interventions;
additional 99 interventions were performed to maintain
patency, equating to an average of 2.2 further interventions
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Table 3: Predictors of postintervention primary patency after stent insertion.
Variables Unadjusted Cox analysis Adjusted Cox analysis
𝑝 value Hazards ratio (95% CI) 𝑝 value Hazards ratio (95% CI)
Patient age 0.78 1.0 (0.96–1.0) — —
Male gender 0.20 1.6 (0.79–3.0) — —
Indigenous ethnicity1 0.49 0.79 (0.40–1.5) — —
Diabetes 0.62 1.3 (0.52–3.0) — —
Vascular disease 0.85 1.1 (0.54–2.1) — —
Native AVF 0.11 0.52 (0.24–1.2) — —
Access age <12 months 0.0043 3.1 (1.4–6.9) 0.0029 3.5 (1.5–7.8)
Upper arm lesion 0.0067 5.2 (1.6–17) 0.0084 5.1 (1.5–17)
Covered stent 0.43 0.73 (0.33–1.6) — —
Antiplatelet 0.99 1.0 (0.51–1.9) — —
1Aboriginal or Torres Strait Islander ethnicity.
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Figure 2: Kaplan-Meier estimate of postintervention primary
patency after stent placement.
per patient after the index stent deployment. The anatomical
and clinical success rate was 98% (97/99 interventions).
Twelve cases required one additional intervention to main-
tain patency. Five cases required further two interventions,
seven cases required further three interventions, two cases
required further four interventions, three cases required fur-
ther five interventions, two cases required further six inter-
ventions, and two cases required further seven interventions.
Fifty-eight out of 99 (59%) of the additional interventions
to maintain patency were related to in-stent or peri-stent
restenosis.
In multivariate Cox regression, upper arm lesions and
access age less than one year at stent insertion were the only
factors associated with reduced postintervention primary
patency (adjusted hazards ratio [HR] 5.1, 95% confidence
interval [CI] 1.5–17, 𝑝 = 0.0084, and HR 3.5, 95% CI 1.5–
7.8, 𝑝 = 0.0029, resp., Table 3). There was no significant
association between any of the other tested variables and
postintervention primary patency (Table 3).
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Figure 3: Kaplan-Meier estimate of postintervention secondary
patency after stent placement.
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Figure 4: Postintervention primary patency for stents placed at
seven treatment areas. Area 2: arteriovenous anastomosis; Area 3:
juxta-anastomosis; Area 4: forearm venous outflow; Area 5: upper
arm venous outflow; Area 6: cephalic arch; Area 7: central veins.
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4. Discussion
Resistant or recurrent stenosis throughout the access circuit
poses challenges in terms of providing optimal hemodialysis
treatment. In this study, stent placement to treat upper arm
lesions and in access less than 12months of age was associated
with increased risk of primary patency loss. Twelve-month
poststent primary and secondary patency rates of 46% and
89%, respectively, were achieved, comparable to studies pub-
lished in the interventional radiology and vascular surgery
literature [1].
Certain anatomical regions of the access circuit are par-
ticularly prone to the development of resistant or recurrent
stenosis. The vein immediately adjacent to the arteriovenous
anastomosis (commonly referred to as juxta-anastomosis) is
a common site of stenosis due, in part, to injury sustained
at the time of “swinging” the vein to form the anastomosis
from the vein’s original anatomical location [11].Theproximal
portion of the cephalic vein (known as the cephalic arch) is
similarly problematic due to the anatomy/morphology of the
vein, presence of valves, and extrinsic compression from the
clavipectoral fascia, all of which limit vascular remodeling
[12]. In this study, more than half of all stents (56%) were at
these two discrete locations.
This study found that more central lesions such as those
throughout the upper arm venous outflow, cephalic arch,
and central veins had poorer patency after treatment with
stents compared to juxta-anastomotic lesions (for all types of
access) and forearm venous outflow lesions (Figure 4). This
reinforces clinical observations that brachiocephalic AVFs
can be particularly problematic and prone to recurrent steno-
sis, particularly at the cephalic arch. This is consistent with
one of the largest studies reporting the outcome of 135 stent
procedures, which found themean time to reinterventionwas
significantly longer for forearmAVFs compared to upper arm
AVFs [13].
This findingwas confirmed after adjustment for other risk
factors in multivariate Cox regression, where stent placement
in upper arm lesions was associated with reduced poststent
primary patency compared to forearm lesions. This may
be related to high flow rates and possibly reflect the role
of hemodynamic stress in the development of neointimal
hyperplasia. Our findings are supported by studies of both
balloon angioplasty and stent placement that reported that
interventions in upper arm access were associated with
reduced postintervention primary patency [8, 14, 15]. How-
ever, this association has not been consistently reported [16,
17] and remains to be confirmed in larger prospective studies.
Stent placement in arteriovenous access less than 12
months of age was associated with reduced postintervention
primary patency. AVFs that develop stenosis in the first six to
12months after creation are likely to be intrinsically defective;
the early development of stenosis in a previously healthy
vein after arteriovenous access formation is a reflection of
accelerated neointimal hyperplasia [5]. It is unsurprising then
that restenosis is more likely after stent insertion for these
patients who developed problematic stenoses in relatively
new AVFs.
Although antiplatelet therapy has been shown to reduce
access thrombosis [18], we found no association between
antiplatelet therapy and poststent patency.Whilst antiplatelet
therapy has endothelial protective benefits in the arterial
system, similar effects in the venous system have yet to be
demonstrated.
The observational nature of this study precluded our
ability to definitively answer the question of which type of
stent provides superior patency. Covered stents were only
used to treat more proximal lesions such as cephalic arch
and central stenosis. On the other hand, nitinol stents were
used throughout the access circuit. One small randomized
trial found that covered stents provided superior patency
compared to nitinol stents for the treatment of recurrent
cephalic arch stenosis [19]. A recently published randomized
trial also found that covered stent placement for cephalic
arch stenosis provided both superior access circuit primary
patency and target lesion primary patency compared to
balloon angioplasty alone [20]. This builds upon increasing
evidence, most notably the FLAIR trial [21] and presented
results of REVISE and RENOVA, that covered stents prolong
access circuit patency in graft-vein anastomotic stenosis
compared to balloon angioplasty. The results from this study
are likely to reflect the small number of covered stents
used and discrepancies in the location of covered stent
placement.
This study demonstrated that secondary patency, which
reflects continued function of the access, was 85% two years
after initial stent placement. In order to provide sustained
dialysis using the same access, an average of 2.2 additional
interventions per access were required. The vast majority
of additional interventions were balloon angioplasties. Of
these, approximately 41% were performed for newly devel-
oped lesions, slightly less than previously reported in other
studies [16]. In most cases, angioplasty was required at the
site of stent placement either for in-stent or for peri-stent
stenosis.
It is important to note that endothelial injury from
repeated balloon angioplasty contributes to the formation
of neointimal hyperplasia. Previous studies have demon-
strated that repeated angioplasty is associated with increas-
ing cellular proliferation of treated lesions [22]. Aggressive
smooth muscle and myofibroblast proliferation due to stent
related luminal mismatch causing turbulent flow and altered
hemodynamics are important in the pathogenesis of in-
stent and peri-stent restenosis [23–25]. The presence of the
stent itself also contributes to the pathogenesis of neoin-
timal hyperplasia by attracting macrophages and inducing
the expression of a cascade of proinflammatory cytokines
[24].
Despite the need for repeated interventions at different
intervals, there are several potential advantages of using
endovascular stents in comparison to open surgical repair.
Stent placement avoids the need for hospitalization; all
procedures were performed in a radiology angiographic suite
without interruption to patients’ dialysis schedules. They
are particularly useful for the treatment of central stenosis
[26]. Open surgical repair of these lesions is technically
complex and highly demanding of patients and is usually
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only considered once endovascular options are exhausted or
ineffective [26]. Demographic changes in dialysis populations
mean that more elderly patients with vascular comorbidities
are commencing hemodialysis [27]. It is vitally important to
preserve sites for future access creation in these patients with
relatively poor peripheral vasculature.
There are some important considerations required prior
to stent placement. For juxta-anastomotic stenosis in radio-
cephalic AVFs, surgical revision with formation of a more
proximal anastomosis may be preferred because there is an
adequate length of cephalic vein available for cannulation
in comparison to upper arm AVFs [28]. Juxta-anastomotic
stenosis in upper arm access is often located at the elbow
flexure crease, which can make stents prone to fractures [1].
Similarly, at the cephalic arch, repeated movement of the
upper arm girdle can lead to stent migration, particularly
if the stent has not endothelialized, resulting in axillary
vein thrombosis and occlusion [1]. Complications such as
stent graft infection and damage from cannulation have also
been reported [29]. We did not observe any of these serious
complications in our study.
This was a retrospective study, with the inherent draw-
backs of such an approach. Comparison with other percuta-
neous interventions (e.g., drug-eluting and cutting balloon
angioplasty) and surgical repair were beyond the scope of
this study. Without this comparison, it was not possible
to extrapolate from the data that secondary patency rates
observed were directly attributable to stent placement. It is
likely that other confounding factors specific to our center
such as a dedicated nurse practitioner vascular access coor-
dinator, access surveillance protocols, and an interventional
nephrology led service model influenced the reported out-
comes. The cost-benefit of repeated angioplasties compared
to surgical correction is an important consideration that
warrants further investigation. Future randomized trials are
needed to assess the utility of covered stents to treat recurrent
stenosis, particularly at the cephalic arch in patients with
brachiocephalic AVFs.
5. Conclusion
This study demonstrated that resistant or recurrent stenosis
could be successfully treated by endovascular stent place-
ment, although multiple procedures are required to maintain
patency. Stent placement for upper arm lesions and in
arteriovenous access less than 12months of agewas associated
with reduced postintervention primary patency.
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